Navigation Links
Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells

Researchers have found a drug containing parts of diptheria toxin as a way to prompt the immune system for recognizing and killing tumour //cell of patients suffering from advanced melanoma (Skin Cancer)

In the first part of a phase II clinical trial to test the drug denileukin diftitox (also known as DAB (389) IL2 or ONTAK) in melanoma, five out of seven patients with stage IV disease experienced significant regression or stabilisation of both tumours and metastases. The two other patients in whom the disease progressed were on a lower dose of the drug. All the patients are still alive after 12 months.

Dr Jason Chesney, associate director for translational research at the JG Brown Cancer Center, University of Louisville, Kentucky, USA, told a news briefing at the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Thursday 9 November): 'We are seeing some exciting results in stage IV melanoma patients whose median life expectancy is normally only about eight months. The phase II trial is continuing to examine the efficacy of denileukin diftitox in patients with melanoma.'

The immune system that attacks cancer cells in humans depends on a balance between T cells, which specifically recognise and attack antigens such as tumour cells, and suppressive or regulatory T cells (Tregs), which turn off activated immune cells in order to prevent autoimmunity.

Dr Chesney explained: 'Recently a subset of regulatory T cells has been found to directly suppress the activation of the anti-tumour T cells, but it was also discovered that, if the Tregs were depleted by targeting them with denileukin diftitox, then particular T cells in the immune system known as CD8+ T lymphocytes were able to attack and kill the melanoma cells in mice.'

Denileukin diftitox is a fusion protein made up of amino acid sequences for the diptheria toxin and the T cell growth factor, interleukin 2 (IL2). It targets Tre gs that have IL2 receptors on their cell surface, and it binds to part of the receptor called CD25. Once it reaches the inside of the cell it prevents protein synthesis, which leads to cell death within hours.

'We thought that if denileukin diftitox could selectively deplete Tregs in patients with melanoma, this would allow the CD8+ T cells to do their job of recognising and attacking the melanoma cells,' said Dr Chesney.

Dr Chesney and his colleagues gave seven patients with stage IV melanoma nine or twelve micrograms per kilogram of body weight daily for four days, every three weeks for four cycles. The two patients on the lower dose had newly detectable tumours and tumour growth after two cycles. However, the five patients on the higher dose experienced significant regression of several metastatic tumours after four cycles, including subcutaneous tumours and metastases in the liver and lymph nodes.

One patient had two tumours on the leg that had died and became infected, requiring surgery. When the researchers examined the tumour tissue they found that it was surrounded by CD8+ T lymphocytes. 'This meant that the lymphocytes had been successfully activated to attack the tumour, which consequently had died. We also found that the concentration of Tregs in this patient decreased by more than a half after the second day's dose of denileukin diftitox,' said Dr Chesney.

'To our knowledge, this is the only trial to study the effects of Treg depletion in human cancer patients. From the results, we conclude that depleting Treg cells in patients with melanoma may allow the immune system to be activated successfully to kill cancer cells. These patients have survived longer than the median average life expectancy of a patient with stage IV melanoma.

'We also believe that, in the future, immunotherapies that depend on depleting Treg cells may prove to be useful in all types of cancer.'

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Toxins linked with pregnancy loss
2. Toxin connected to Flesh-eating Pneumonia in Kids
3. Vegetables decrease Tobacco Toxins
4. Toxin injections support stroke associated spasticity
5. Indians Stay Away from Coke, Pepsi After Toxin Scare
6. Toxin from the sea to relieve pain
7. Toxin Identified For Alzheimer’s Diseas
8. UN Fears Melting Of Ice Would Concentrate Toxins in the Chinese Water Supply
9. Gold Nanoparticles Are Good Detectors Biological Toxins
10. Appearance Of Facial Scars Improved By Botulinum Toxin
11. "Beach to Bedside" Study Focuses on Effects of Inhaled Toxins
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... Sterling, VA (PRWEB) , ... April 29, 2016 ... ... Americans with student loans more flexibility in repaying their loans, more information about ... at a time when total outstanding student loan debt, including federal and private ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... Hills, CA (PRWEB) , ... April 29, 2016 , ... ... of devices and products for the head and neck/ear, nose and throat specialty, has ... Device , The KOTLER NASAL AIRWAY™ is a newly patented safety device ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
Breaking Medicine Technology: